A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SEARCH)

Antengene

Status and phase: Completed; Phase 2

Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Treatments: Drug: ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle

Study type: Interventional

Funder types: Industry

Identifiers

NCT03992339

ATG-010-DLBCL-001

Details and patient eligibility

About

This is an open-label, single arm, and registered study of ATG-010 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Full description

This is an open-label, single arm, and registered study. About 60 patients with relapsed/refractory DLBCL plan to be enrolled in about 10 study sites of the study. It is planned that at least 50% (~30 patients) will have the GCB subtype of DLBCL. Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle. Patients should remain on the study treatment of ATG-010, until either PD or occurrence of unacceptable toxicity.

Enrollment: 60 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. The patient must provide informed consent form (ICF) prior to the first screening procedure.
2. Age ≥18 years.
3. ECOG performance status of ≤ 2.
4. Patients should have estimated life expectancy of >3 months at study entry.
5. Previously treated, pathologically confirmed de novo DLBCL, or DLBCL transformed from previously diagnosed indolent lymphoma (e.g., follicular lymphoma).
6. Patients must have received at least 2 but no more than 5 previous systemic regimens for the treatment of their de novo or transformed DLBCL.
7. Documented clinical or radiographic evidence of progressive DLBCL prior to dosing.
8. Patients must have measurable disease per the revised criteria for response assessment of lymphoma (Cheson, 2014).
9. Patients must not be eligible for high-dose chemotherapy with autologous stem cell transplantation rescue.

Exclusion criteria

1. Patients who are pregnant or lactating.
2. DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma, composite lymphoma (Hodgkin's lymphoma +NHL), or DLBCL transformed from diseases other than indolent NHL or Richter's.
3. Primary mediastinal (thymic) large B-cell lymphoma.
4. Known central nervous system lymphoma or meningeal involvement.
5. Patients whose most recent systemic anticancer therapy include radiation, chemotherapy, immunotherapy, radio-immunotherapy, or any other anticancer therapy other than glucocorticoids < 6 weeks prior to first dose of study drug.
6. Patients who have not recovered to Grade ≤ 1 clinically significant adverse events, or to their baseline, from their most recent systemic anti-DLBCL therapy.
7. Patients with active graft-versus-host disease after allogeneic stem cell transplantation. At least 4 months must have elapsed since completion of allogeneic stem cell transplantation.
8. Major surgery within 2 weeks of first dose of study treatment of ATG-010.
9. Any life-threatening illness, medical condition or organ system dysfunction which, in the Investigator's opinion, could compromise the patient's safety.
10. Active hepatitis B virus or hepatitis C virus infection.
11. Known human immunodeficiency virus infection.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

60 participants in 1 patient group

ATG-010

Experimental group

Description:

Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010.

Treatment:

Drug: ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle